In case you missed it: Dec. 7 to Dec. 11


This week’s top articles included:

Reversing endometrial hyperplasia with levonorgestrel-intrauterine system: a Cochrane review

In the largest meta-analysis study to date, researchers find that a levonorgestrel-intrauterine system (LNG-IUS) used for 3 to 6 months is likely more effective than non‐intrauterine progestogens for reversing endometrial hyperplasia (EH).

A look back at 2020

What a year 2020 has been! We hope to look back on it and recognize it as an outlier or anomaly—hoping life will at some point return to normal.

Protocols for High-Risk Pregnancies, 7th Edition

Snapshot: Protocol 56 - Shoulder Dystocia

Managing fetal sex discordance in cfDNA

This article presents a clinical algorithm and four cases to consider.

Lymphangioma circumscriptum

Could you recognize this rare vulvar condition?

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.